Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

Key facts

Sponsor

Western Galilee Hospital-Nahariya

Enrollment

70 target

Eligibility

18 years · All sexes

Timeline

2024 – 2031

Study locations (1)

• Galilee Medical Center, Nahariya, Israel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Twin-reversed arterial perfusion sequence

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06550011
  Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
  Avirmax Biopharma Inc
• ACTIVE NOT RECRUITINGNCT07194915
  Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection (TORPIDS-3)
  University of Oxford
• RECRUITINGNCT06412822
  Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone
  Brugmann University Hospital
• RECRUITINGNANCT05711173
  Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
  University Hospital, Bordeaux
• ACTIVE NOT RECRUITINGNCT07185646
  Mechanistic Study of SPARC-Mediated Regulation of Neutrophil Extracellular Trap Formation in the Brain Metastatic Microenvironment of Breast Cancer
  Second Xiangya Hospital of Central South University
• RECRUITINGNCT05056857
  Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04784416
  Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
  NYU Langone Health
• ACTIVE NOT RECRUITINGPHASE2NCT03787680
  Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
  University of Michigan Rogel Cancer Center

See all trials for Twin-reversed arterial perfusion sequence →